S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Editas Medicine Stock Price, Forecast & Analysis (NASDAQ:EDIT)

$23.15
+0.29 (+1.27 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$22.51
Now: $23.15
$23.50
50-Day Range
$19.36
MA: $21.14
$23.11
52-Week Range
$17.80
Now: $23.15
$32.46
Volume533,500 shs
Average Volume758,570 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.94 million
Book Value$4.09 per share

Profitability

Net Income$-109,950,000.00
Net Margins-842.47%

Miscellaneous

Employees133
Market Cap$1.19 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) released its earnings results on Tuesday, November, 12th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.07. The firm earned $3.90 million during the quarter, compared to analysts' expectations of $4.72 million. Editas Medicine had a negative return on equity of 56.53% and a negative net margin of 842.47%. The company's quarterly revenue was down 73.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.32) earnings per share. View Editas Medicine's Earnings History.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Editas Medicine.

What price target have analysts set for EDIT?

8 brokers have issued twelve-month price targets for Editas Medicine's stock. Their forecasts range from $29.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $38.00 in the next year. This suggests a possible upside of 64.1% from the stock's current price. View Analyst Price Targets for Editas Medicine.

What is the consensus analysts' recommendation for Editas Medicine?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:
  • 1. According to Zacks Investment Research, "Editas posted narrower-than-expected loss in Q3 while revenues almost matched estimates. Its lead candidate EDIT-101, which uses CRISPR gene editing to treat LCA10, a genetic illness that causes blindness, is being developed in partnership with Allergan. The disease has a significant unmet need as no therapies are presently approved. A phase I/II dose escalation study on EDIT-101 initiated patient enrolment in July 2019. Editas has some high-profile collaborations with big pharma companies for its CRISPR technology, which provide research support and funds to pursue its pipeline development. It is also developing EDIT-301 for sickle cell disease and beta-thalassemia. However, due to lack of a marketed product, Editas is heavily dependent on its partners for collaboration revenues, which remains a concern. Shares have underperformed year to date." (11/14/2019)
  • 2. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019)

Has Editas Medicine been receiving favorable news coverage?

Media stories about EDIT stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Editas Medicine earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Editas Medicine.

Are investors shorting Editas Medicine?

Editas Medicine saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 7,760,000 shares, a decline of 6.6% from the September 15th total of 8,310,000 shares. Based on an average trading volume of 597,400 shares, the days-to-cover ratio is currently 13.0 days. Approximately 16.3% of the shares of the company are short sold. View Editas Medicine's Current Options Chain.

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Shopify (SHOP), CA (CA) and Advanced Micro Devices (AMD).

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:
  • Dr. Charles Albright, Chief Scientific Officer (Age 61)
  • Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.02%), Sumitomo Mitsui Trust Holdings Inc. (10.02%), Global Thematic Partners LLC (0.69%), California Public Employees Retirement System (0.19%), Mackay Shields LLC (0.12%) and Creative Planning (0.07%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Patriot Financial Group Insurance Agency LLC, Great West Life Assurance Co. Can, Focused Wealth Management Inc, Commonwealth Equity Services LLC, Dupont Capital Management Corp, Coastal Investment Advisors Inc. and Creative Planning. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Cynthia Collins, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., California Public Employees Retirement System, First Trust Advisors LP, Tower Research Capital LLC TRC , Boston Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank and Mackay Shields LLC. View Insider Buying and Selling for Editas Medicine.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $23.15.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.19 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine.

What is Editas Medicine's official website?

The official website for Editas Medicine is http://www.editasmedicine.com/.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel